Helicobacter pylori: Challenges and Advances in Diagnosis, Treatment, and Eradication
DOI:
https://doi.org/10.59675/U216Keywords:
Infection, Helicobacter pylori, Diagnostic, Therapeutic, Challenges.Abstract
A common and extensively distributed "Helicobacter pylori" still poses a serious risk to public health. "H. pylori" infections can cause various stomach problems, such as inflammation, gastroduodenal ulcers, and cancers; therefore, it is essential to discover and treat them early to stop their progression. To reduce or perhaps completely eradicate "H. pylori," people must be informed of the bacteria and the health risks it poses. Raising the bar for the present diagnostic, eradication, and alternate treatment approaches is therefore essential. Furthermore, a succinct review of conventional and innovative methods that have successfully detected and treated "H. pylori" is required. The best diagnostic strategy necessitates considering several variables, including the test and lab equipment that are accessible in addition to the patient's clinical traits. Studying H. pylori's pathophysiology and pathogenic pathways is also necessary, emphasizing the virulence factors that cause infection. As a result, this reappraisal intends to illustrate the several "H. pylori" diagnostic, pathophysiological, therapeutic, and eradication strategies available, highlighting both their benefits and drawbacks. And the emergence of stomach cancer. Noninvasive techniques include stool examinations, breath tests, serological testing, invasive methods like fast urease testing, biopsy, or culture. In conclusion, there have been significant advancements in "H. pylori" testing and treatment, immunizations can eliminate disease.
Downloads
References
Liao, E.C., Yu, C.H., Lai, J.H., Lin, C.C., Chen, C.J., Chang, W.H. and Chien, D.K., 2023. A pilot study of non-invasive diagnostic tools to detect “Helicobacter pylori” infection and peptic ulcer disease. Scientific Reports, 13(1), p.22800. DOI: https://doi.org/10.1038/s41598-023-50266-2
Suerbaum, S.; Michetti, P. “Helicobacter pylori” infection. N. Engl. J. Med. 2002, 347, 1175–1186. [CrossRef] [PubMed] DOI: https://doi.org/10.1056/NEJMra020542
Malfertheiner, P.; Megraud, F.; O’Morain, C.; Bazzoli, F.; El-Omar, E.; Graham, D.; Hunt, R.; Rokkas, T.; Vakil, N.; Kuipers, E.J. Current concepts in the management of “Helicobacter pylori”infection: The Maastricht III Consensus Report. Gut 2007, 56, 772–781. [CrossRef] [PubMed] DOI: https://doi.org/10.1136/gut.2006.101634
Jemilohun, A.C.; Otegbayo, J.A. “Helicobacter pylori” infection: Past, present and future. Pan Afr. Med. J. 2016, 23, 1–15. [CrossRef] DOI: https://doi.org/10.11604/pamj.2016.23.216.8852
Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61:177-240.
Liou JM, Fang YJ, Chen CC, et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, openlabel, randomised trial. Lancet 2016;388(10058): 2355–2365. DOI: https://doi.org/10.1016/S0140-6736(16)31409-X
Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol 2014; 20:5191–5204. DOI: https://doi.org/10.3748/wjg.v20.i18.5191
Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of “Helicobacter pylori” infection in China and the USA. Gut Pathog 2016; 8:8. DOI: https://doi.org/10.1186/s13099-016-0091-7
Pormohammad, A.; Ghotaslou, R.; Leylabadlo, H.E.; Nasiri, M.J.; Dabiri, H.; Hashemi, Risk of gastric cancer in association with “Helicobacter pylori”different virulence factors: A systematic review and meta-Analysis. Microb. Pathog. 2018, 118, 214–219. [CrossRef] [PubMed] DOI: https://doi.org/10.1016/j.micpath.2018.03.004
Sgouras, D.; Tegtmeyer, N.; Wessler, S. Activity and Functional Importance of “Helicobacter pylori” Virulence Factors. In Advances in Experimental Medicine and Biology; Kluwer Academic Publishers: Boston, MA, USA, 2019 DOI: https://doi.org/10.1007/5584_2019_358
Olivera-Severo, D.; Uberti, A.F.; Marques, M.S.; Pinto, M.T.; Gomez-Lazaro, M.; Figueiredo, C.; Leite, M.; Carlini, C.R. A New Role for “Helicobacter pylori” Urease: Contributions to Angiogenesis. Front. Microbiol. 2017, 8, 1883. [CrossRef] DOI: https://doi.org/10.3389/fmicb.2017.01883
Zamani, M.; Ebrahimtabar, F.; Zamani, V.; Miller, W.; Alizadeh-Navaei, R.; Shokri-Shirvani, J.; Derakhshan, M. Systematic review with meta-analysis: The worldwide prevalence of “Helicobacter pylori” infection. Aliment. Pharmacol. Ther. 2018, 47, 868–876. [CrossRef] DOI: https://doi.org/10.1111/apt.14561
Savoldi, A.; Carrara, E.; Graham, D.Y.; Conti, M.; Tacconelli, E. Prevalence of antibiotic resistance in Helicobacter pylori: Asystematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018, 155, 1372–1382.e17. [CrossRef] DOI: https://doi.org/10.1053/j.gastro.2018.07.007
Reshetnyak, V.I.; Burmistrov, A.I.; Maev, I.V. Helicobacter pylori: Commensal, symbiont or pathogen? World J. Gastroenterol. 2021,27, 545. [CrossRef] DOI: https://doi.org/10.3748/wjg.v27.i7.545
Burucoa, C.; Axon, A. Epidemiology of “Helicobacter pylori” infection. Helicobacter 2017, 22, e12403. [CrossRef] DOI: https://doi.org/10.1111/hel.12403
Pucułek, M.; Machlowska, J.; Wierzbicki, R.; Baj, J.; Maciejewski, R.; Sitarz, R. “Helicobacter pylori” associated factors in the development of gastric cancer with special reference to the early-onset subtype. Oncotarget 2018, 9, 31146. [CrossRef] DOI: https://doi.org/10.18632/oncotarget.25757
Sharndama, H.C.; Mba, I.E. Helicobacter pylori: An up-to-date overview on the virulence and pathogenesis mechanisms. Braz. J.Microbiol. 2022, 53, 1–18. [CrossRef] DOI: https://doi.org/10.1007/s42770-021-00675-0
Saxena, A.; Mukhopadhyay, A.K.; Nandi, S.P. Helicobacter pylori: Perturbation and restoration of gut microbiome. J. Biosci. 2020,45, 1–15. [CrossRef] DOI: https://doi.org/10.1007/s12038-020-00078-7
Cardos, A.I.; Maghiar, A.; Zaha, D.C.; Pop, O.; Fritea, L.; Miere, F.; Cavalu, S. Evolution of Diagnostic Methods for “Helicobacter pylori” Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics 2022, 12,508. [CrossRef] DOI: https://doi.org/10.3390/diagnostics12020508
Keskin, M.; Yavuz, A. A novel rapid and accurate method for detecting Helicobacter pylori: The modified antigen test. Eur. Rev. Med. Pharm. Sci. 2022, 26, 1148–1155
Chiariotti L, Angrisano T, Keller S, Florio E, Affinito O, Pallante P, Perrino C, Pero R, Lembo F. 2013. Epigenetic modifications induced by “Helicobacter pylori” infection through a direct microbe-gastric epithelial cells crosstalk. Med Microbiol Immunol 202:327–337. DOI: https://doi.org/10.1007/s00430-013-0301-6
Sharafutdinov I, Backert S, Tegtmeyer N. The “Helicobacter pylori” type IV secretion system upregulates epithelial cortactin expression by a CagA- and JNK-dependent pathway. Cell Microbiol 2021; 23: e13376. DOI: https://doi.org/10.1111/cmi.13376
Cao L, Zhu S, Lu H, Soutto M, Bhat N, Chen Z, Peng D, Lin J, Lu J, Li P, Zheng C, Huang C, El-Rifai, W. Helicobacter pylori–induced RASAL2 through activation of Nuclear Factor-κB promotes gastric tumorigenesis via β-catenin signaling axis. Gastroenterology 2022; 162: 1716-1731.e17. DOI: https://doi.org/10.1053/j.gastro.2022.01.046
Jia Y, Liu Y, Zhu J, Liu L, Ma X, Liu D, Han S, Zhang L, Ling ZQ, Wang Y. DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway. J Cell Mol Med 2022; 26: 1943- 1954. DOI: https://doi.org/10.1111/jcmm.17219
Aziz F, Chakraborty A, Liu K, Zhang T, Li X, Du R, Monts J, Xu G, Li Y, Bai R, Dong Z. Gastric tumorigenesis induced by combining “Helicobacter pylori” infection and chronic alcohol through IL-10 inhibition. Carcinogenesis 2022; 43: 126-139. DOI: https://doi.org/10.1093/carcin/bgab114
Liu Z, Wu X, Tian Y, Zhang W, Qiao S, Xu W, Liu Y, Wang S. “H. pylori” infection induces CXCL8 expression and promotes gastric cancer progress through downregulating KLF4. Mol Carcinog 2021; 60: 524-537. DOI: https://doi.org/10.1002/mc.23309
Aydin EM, Demir TD, Seymen N, Said SS, Oktem-Okullu S, Tiftikci A, Cicek B, Tokat F, Tozun N, Ince U, Sezerman U, Sayi-Yazgan A. The crosstalk between “H. pylori” virulence factors and the PD1: PD-L1 immune checkpoint inhibitors in progression to gastric cancer. Immunol Lett 2021; 239: 1-11. DOI: https://doi.org/10.1016/j.imlet.2021.06.009
Chen HY, Hu Y, Xu XB, Zhou YA, Li NS, He C, Xie C, Lu NH, Zhu Y. Upregulation of oncogene Activin A receptor type I by “Helicobacter pylori” infection promotes gastric intestinal metaplasia via regulating CDX2. Helico bacter 2021; 26: e12849. DOI: https://doi.org/10.1111/hel.12849
Fatema, J., Khan, A. H., Uddin, M. J., Rahman, M. H., Saha, M., Safwath, S. A., et al. (2015). Chronic gastritis and its association with “H. pylori” infection. Mymensingh Med.J. 24 (4), 717–722
Ali, A. and AlHussaini, K.I., 2024. Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies. Microorganisms, 12(1), p.222. DOI: https://doi.org/10.3390/microorganisms12010222
Zandi F, Shirzad H, Bagheri N, et al. “Helicobacter pylori” and IL-23R gene polymorphism role in degeneration of gastric mucosa. American Journal of BioMedicine 2014;2(3):176- 188. DOI: https://doi.org/10.18081/2333-5106/014-03/176-188
Montecucco C, Rapuolli R. Living dangerously: how “Helicobacter pylori” survives in the human stomach. Nat Rev Mol Cell Biol. 2001;2(6):457–466. DOI: https://doi.org/10.1038/35073084
Tan, J., Zhang, X., Wang, X., Xu, C., Chang, S., Wu, H., et al. (2021). Structural basisof assembly and torque transmission of the bacterial flagellar motor. Cell 184 (10),2665–267934. DOI: https://doi.org/10.1016/j.cell.2021.03.057
Polk DB and Peek RM Jr: Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10: 403-414, 2010. DOI: https://doi.org/10.1038/nrc2857
González CA, Figueiredo C, Lic CB, et al: “Helicobacter pylori” cagA and “VacA” genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol 106: 867-874,2011 DOI: https://doi.org/10.1038/ajg.2011.1
Boonyanugomol W, Chomvarin C, Baik SC, Song JY, Hahnvajanawong C, Kim KM, et al. Role of cagA-positive “Helicobacter pylori”on cell proliferation, apoptosis, and inflammation in biliary cells. Dig Dis Sci 2011; 56:1682e92. DOI: https://doi.org/10.1007/s10620-010-1512-y
Kikuchi K, Murata-Kamiya N, Kondo S, Hatakeyama M.”Helicobacter pylori”stimulates epithelial cell migration via CagA-mediated perturbation of host cell signaling. MicrobesInfect 2012;14:470e6. DOI: https://doi.org/10.1016/j.micinf.2011.12.003
Boonyanugomol W, Chomvarin C, Hahnvajanawong C,Sripa B, Kaparakis-Liaskos M, Ferrero RL. “Helicobacter pylori”cag pathogenicity island (cagPAI) involved in bacterial internalization and IL-8 induced responses via NOD1- and MyD88-dependent mechanisms in human biliary epithelial cells. PLoS One 2013;8:e77358. DOI: https://doi.org/10.1371/journal.pone.0077358
Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K,Graham DY. Relationship between “Helicobacter pylori” iceA,cagA, and “VacA” status and clinical outcome: studies in four different countries. J Clin Microbiol 1999; 37: 2274–9. DOI: https://doi.org/10.1128/JCM.37.7.2274-2279.1999
Peek RM Jr, Thompson SA, Donahue JP, et al. Adherence to gastric epithelial cells induces expression of a “Helicobacter pylori” gene, iceA, that is associated with clinical outcome. Proc Assoc Am Physicians 1998; 110: 531–44.
Peek RM Jr, Miller GG, Tham KT, et al. Heightened inam- matory response and cytokine expression in vivo to CagA»“Helicobacter pylori”strains. Lab Invest 1995; 73: 760–70.
Mauch F, Bode G, Ditschuneit H, Malfertheiner P. Demonstration of a phospholipid-rich zone in the human gastricephitelium damaged by Helicobacter pylori. Gastroenterology1993; 105: 1698–704. DOI: https://doi.org/10.1016/0016-5085(93)91065-P
McGee DJ, May CA, Garner RM, Himpsl JM, Mobley HLT.I solation of “Helicobacter pylori” genes that modulate urease activity. J Bacteriol 1999; 181: 2477–84. DOI: https://doi.org/10.1128/JB.181.8.2477-2484.1999
Simon PM, Good PL, Mobasseri A, Zopf D. Inhibition of “Helicobacter pylori” binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect Immun 1997;65: 750–7. DOI: https://doi.org/10.1128/iai.65.2.750-757.1997
Ilver D, Arnqvist A, Ogren J, et al. “Helicobacter pylori” adhesin binding fucosylated histo-blood group antigens re- vealed by retagging. Science 1998; 279: 373–7. DOI: https://doi.org/10.1126/science.279.5349.373
Rani AA and Fauzi A. Infeksi “Helicobacter pylori” dan Penyakit Gastroduodenal. In: Setiati, S., et al. Buku Ajar Ilmu Penyakit Dalam Edisi Keenam. Jakarta: Interna Publishing 2014; p1772-1779
Atherton, J.C., Blaser, M.J. “Helicobacter pylori” Infections. In :19th Edition Harrison’s Principles of Internal Medicine. USA: Mc Graw Hill Education 2015; p1038-1042.
Hoed CMD and Kuipers EJ. “Helicobacter pylori” infection. In: Magil AJ, Solomon, T, Ryan ET. (eds.) Hunter’s Tropical Medicine and Emerging Infectious Disease 9th ed. London: Saunders Elsevier; 2013. p 428-441
Axon A. “Helicobacter pylori” and public health. Helicobacter 2014;19 Suppl 1: 68-73 [PMID: 25167948 DOI: 10.1111/hel.12155] 6 Lee JH, Park YS, Choi KS, Kim does H, Choi KD, Song HJ, DOI: https://doi.org/10.1111/hel.12155
Lee GH, Jang SJ, Jung HY, Kim JH. Optimal biopsy site for “Helicobacter pylori” detection during endoscopic mucosectomy in patients with extensive gastric atrophy. Helicobacter 2012; 17:405-410 [PMID: 23066901 DOI: 10.1111/j.1523-5378.2012.00972. DOI: https://doi.org/10.1111/j.1523-5378.2012.00972.x
Kato T, Yagi N, Kamada T, Shimbo T, Watanabe H, Ida K. Diagnosis of “Helicobacter pylori” infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc 2013; 25: 508-518 [PMID: 23369058 DOI: 10.1111/den.12031] DOI: https://doi.org/10.1111/den.12031
Cho JH, Chang YW, Jang JY, Shim JJ, Lee CK, Dong SH, Kim HJ, Kim BH, Lee TH, Cho JY. Close observation of gastric mucosal pattern by standard endoscopy can predict “Helicobacter pylori”infection status. J Gastroenterol Hepatol 2013; 28: 279-284 DOI: https://doi.org/10.1111/jgh.12046
Hartman DJ, Owens SR. Are routine ancillary stains required to diagnose Helicobacter infection in gastric biopsy specimens? An institutional quality assurance review. Am J Clin Pathol 2012; 137:255-260 DOI: https://doi.org/10.1309/AJCPD8FFBJ5LSLTE
Batts KP, Ketover S, Kakar S, Krasinskas AM, Mitchell KA, Wilcox R, Westerhoff M, Rank J, Gibson J, Mattia AR, Cummings OW, Davison JM, Naini BV, Dry SM, Yantiss RK. Appropriate use of special stains for identifying Helicobacter pylori: Recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol 2013; 37: e12-e22 DOI: https://doi.org/10.1097/PAS.0000000000000097
Rotimi O, Cairns A, Gray S, Moayyedi P, Dixon MF. Histological identification of Helicobacter pylori: comparison of staining methods. J Clin Pathol 2000; 53: 756-759 DOI: https://doi.org/10.1136/jcp.53.10.756
Yilmaz O, Demiray E. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. World J Gastroenterol 2007; 13: 671-675 DOI: https://doi.org/10.3748/wjg.v13.i5.671
Tajbakhsh S, Samarbaf-Zadeh AR, Moosavian M. Comparison of fluorescent in situ hybridization and histological method for the diagnosis of “Helicobacter pylori” in gastric biopsy samples. Med SciMonit 2008; 14: BR183-BR187
Cerqueira L, Fernandes RM, Ferreira RM, Oleastro M, Carneiro F, Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Figueiredo C, Keevil CW, Vieira MJ, Azevedo NF. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of “Helicobacter pylori” clarithromycin resistance in gastricbiopsy specimens. J Clin Microbiol 2013; 51: 1887-1893 DOI: https://doi.org/10.1128/JCM.00302-13
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of “Helicobacter pylori” infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 DOI: https://doi.org/10.1136/gutjnl-2012-302084
ALzamili, F. and Kadhim, N.J., 2024. Diagnosis Study of Peptic Ulcer in Iraqi Patients Students. Academic International Journal of Medical Sciences, 2(2), pp.12-19. DOI: https://doi.org/10.59675/M223
Momtaz H, Souod N, Dabiri H, Sarshar M. Study of “Helicobacter pylori” genotype status in saliva, dental plaques, stool, and gastric biopsy samples. World J Gastroenterol 2012; 18: 2105-2111 DOI: https://doi.org/10.3748/wjg.v18.i17.2105
Saez J, Belda S, Santibáñez M, Rodríguez JC, Sola-Vera J, Galiana A, Ruiz-García M, Brotons A, López-Girona E, Girona E, Sillero C, Royo G. Real-time PCR for diagnosing “Helicobacter pylori” infection in patients with upper gastrointestinal bleeding: comparison with other classical diagnostic methods. J Clin Microbiol 2012; 50: 3233-3237 DOI: https://doi.org/10.1128/JCM.01205-12
Lehours P, Mégraud F. “Helicobacter pylori” molecular diagnosis. Expert Rev Mol Diagn 2011; 11: 351-355 DOI: https://doi.org/10.1586/erm.11.17
Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of “H. pylori” infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921-1930 DOI: https://doi.org/10.1111/j.1572-0241.2006.00668.x
LIST, E.M., 2017. Standard Treatment guidelines.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Academic International Journal of Medical Update
This work is licensed under a Creative Commons Attribution 4.0 International License.
